CN106279014A - 一种合成苯甘氨酸类衍生物及方法 - Google Patents
一种合成苯甘氨酸类衍生物及方法 Download PDFInfo
- Publication number
- CN106279014A CN106279014A CN201610659271.7A CN201610659271A CN106279014A CN 106279014 A CN106279014 A CN 106279014A CN 201610659271 A CN201610659271 A CN 201610659271A CN 106279014 A CN106279014 A CN 106279014A
- Authority
- CN
- China
- Prior art keywords
- phenyl
- methyl ester
- analog derivative
- mole
- phenylglycine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 21
- 150000005331 phenylglycines Chemical class 0.000 title claims description 13
- 238000003786 synthesis reaction Methods 0.000 title claims description 10
- 230000015572 biosynthetic process Effects 0.000 title claims description 7
- 238000006243 chemical reaction Methods 0.000 claims abstract description 38
- KQSSATDQUYCRGS-UHFFFAOYSA-N methyl glycinate Chemical compound COC(=O)CN KQSSATDQUYCRGS-UHFFFAOYSA-N 0.000 claims abstract description 26
- 230000026030 halogenation Effects 0.000 claims abstract description 9
- 238000005658 halogenation reaction Methods 0.000 claims abstract description 9
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 9
- 239000000758 substrate Substances 0.000 claims abstract description 7
- 125000003118 aryl group Chemical group 0.000 claims abstract description 3
- 239000000047 product Substances 0.000 claims description 26
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 17
- 238000006254 arylation reaction Methods 0.000 claims description 13
- 238000004440 column chromatography Methods 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 claims description 11
- 239000000741 silica gel Substances 0.000 claims description 11
- 229910002027 silica gel Inorganic materials 0.000 claims description 11
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 claims description 9
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 claims description 9
- 229910052763 palladium Inorganic materials 0.000 claims description 8
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 claims description 5
- DORMTBIPKNPJPY-UHFFFAOYSA-N acetic acid;iodobenzene Chemical compound CC(O)=O.IC1=CC=CC=C1 DORMTBIPKNPJPY-UHFFFAOYSA-N 0.000 claims description 5
- 229940071536 silver acetate Drugs 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 3
- 125000003158 alcohol group Chemical group 0.000 claims description 2
- JODVAFCKAKAMSC-UHFFFAOYSA-N 2-phenyl-1H-pyridine-2-carboxamide Chemical compound C1(=CC=CC=C1)C1(NC=CC=C1)C(=O)N JODVAFCKAKAMSC-UHFFFAOYSA-N 0.000 claims 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 3
- 239000012043 crude product Substances 0.000 claims 3
- 229960001866 silicon dioxide Drugs 0.000 claims 3
- 239000004215 Carbon black (E152) Substances 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 229930195733 hydrocarbon Natural products 0.000 claims 2
- 150000002430 hydrocarbons Chemical class 0.000 claims 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical class CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 229960003750 ethyl chloride Drugs 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 1
- 150000003333 secondary alcohols Chemical class 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 abstract description 9
- 150000001413 amino acids Chemical class 0.000 abstract description 8
- -1 α-phenylglycine derivative compounds Chemical class 0.000 abstract description 7
- 150000003862 amino acid derivatives Chemical class 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 125000000524 functional group Chemical group 0.000 abstract description 2
- 238000007306 functionalization reaction Methods 0.000 abstract description 2
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 abstract description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 238000006555 catalytic reaction Methods 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000006257 total synthesis reaction Methods 0.000 abstract 1
- 238000005481 NMR spectroscopy Methods 0.000 description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000002390 rotary evaporation Methods 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 5
- 238000010499 C–H functionalization reaction Methods 0.000 description 4
- ZGUNAGUHMKGQNY-SSDOTTSWSA-N D-alpha-phenylglycine Chemical compound OC(=O)[C@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-SSDOTTSWSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229940081066 picolinic acid Drugs 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- ZGUNAGUHMKGQNY-UHFFFAOYSA-N alpha-phenylglycine Chemical compound OC(=O)C(N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 150000008424 iodobenzenes Chemical class 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- BHFLUDRTVIDDOR-MRVPVSSYSA-N methyl (2r)-2-amino-2-phenylacetate Chemical compound COC(=O)[C@H](N)C1=CC=CC=C1 BHFLUDRTVIDDOR-MRVPVSSYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- UCCUXODGPMAHRL-UHFFFAOYSA-N 1-bromo-4-iodobenzene Chemical compound BrC1=CC=C(I)C=C1 UCCUXODGPMAHRL-UHFFFAOYSA-N 0.000 description 1
- GWQSENYKCGJTRI-UHFFFAOYSA-N 1-chloro-4-iodobenzene Chemical compound ClC1=CC=C(I)C=C1 GWQSENYKCGJTRI-UHFFFAOYSA-N 0.000 description 1
- UDHAWRUAECEBHC-UHFFFAOYSA-N 1-iodo-4-methylbenzene Chemical compound CC1=CC=C(I)C=C1 UDHAWRUAECEBHC-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- DUNGTFMGZITLFT-UHFFFAOYSA-N COC(C(c1ccccc1)NC1OC1c1ncccc1)=O Chemical compound COC(C(c1ccccc1)NC1OC1c1ncccc1)=O DUNGTFMGZITLFT-UHFFFAOYSA-N 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- QXLOVPXUZAOKBL-AWEZNQCLSA-N methyl (2s)-3-(1h-indol-3-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical group C1=CC=C2C(C[C@@H](C(=O)OC)NC(=O)OC(C)(C)C)=CNC2=C1 QXLOVPXUZAOKBL-AWEZNQCLSA-N 0.000 description 1
- BHFLUDRTVIDDOR-UHFFFAOYSA-N methyl 2-amino-2-phenylacetate Chemical compound COC(=O)C(N)C1=CC=CC=C1 BHFLUDRTVIDDOR-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000012450 pharmaceutical intermediate Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- PSAYJRPASWETSH-UHFFFAOYSA-N pyridine-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CC=N1 PSAYJRPASWETSH-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyridine Compounds (AREA)
Abstract
本发明公开了一种合成α‑苯甘氨酸衍生物类化合物的方法。在醋酸钯的催化下,以α‑苯基‑α‑吡啶酰胺甘氨酸甲酯为底物,吡啶酰胺为导向官能团,在底物苯环的邻位上进行C‑H双官能团化,包括芳基化、烷氧基化、卤化。本发明能有效地合成含手性中心的氨基酸小分子,达到对氨基酸侧链进行修饰的目的。此方法条件温和,省去了预官能团化过程,减少了反应步骤,具有较高的原子经济性。对简单的氨基酸小分子结构进行修饰,得到稍复杂的氨基酸类衍生物,可进一步用于医药或全合成等研究,在药物化学等领域具有较高的潜在价值和广阔的应用前景。
Description
技术领域
本发明属于有机合成化学技术领域,具体涉及一种合成苯甘氨酸类衍生物及方法。
背景技术
苯甘氨酸类衍生物是一类重要的医药中间体,常用于合成氨苄青霉素、头孢氨苄、头孢拉定等β-内酰胺类抗生素,也用于合成多肽激素和多种农药,在生物化学、药物化学等领域具有巨大的发展潜力和广阔的应用前景。
近年来,随着生物体化学的不断深入研究,氨基酸这类小分子生物活性物质逐渐引起人们关注。利用化学合成方法对简单的氨基酸结构进行修饰与改造,得到系列氨基酸类衍生物,从而应用于生物肽或药物研究,具有十分重要的意义。其中,通过过渡金属催化的C-H活化对氨基酸进行官能团化相较于传统的化学合成方法,在一定程度上展现了其高效性、易操作性、原子经济性等优势。
目前常见报道的利用C-H活化方法修饰的氨基酸结构有苯丙氨酸、酪氨酸、色氨酸、组氨酸等天然氨基酸。2009年,Smith和Maleczka首次利用金属铱催化C-H活化选择性地在N-Boc-色氨酸甲酯的C-2位合成C-B键。(VenkataA.Kallepalli,Feng Shi,SulagnaPaul,Edith N.Onyeozili,Robert E.Maleczka,Jr.,and Milton R.Smith,III.J.Org.Chem.2009,74,9199.)随后铱催化C-H活化被应用于苯丙氨酸、含芳杂环的氨基酸等。2010年,Vickers等报道了钯催化的N-三氟乙酰胺导向的苯丙氨酸、酪氨酸、苯基丁氨酸的邻位C-H乙酰氧化。(Chris J.Vickers,Tian-Sheng Mei,and Jin-QuanYu.Org.Lett.2010,12,2511.)2008年,Yu课题组将钯催化的C-H碘化应用于苯丙氨酸和酪氨酸,此处用的碘源为醋酸碘苯。(Li,Jiao-Jie,Tian-Sheng Mei,and Jin-QuanYu.Angew.Chem.,Int.Ed.2008,47,6452.)2009年,Bedford等报道了铑催化的酪氨酸邻位的芳基化。(Bedford RB,HaddowM F,Webster RL,Mitchell CJ.J.Org.Biomol.Chem.2009,7,3119.)随后色氨酸和组氨酸的芳基化也被报道,用的是钯催化剂,但反应体系中含配体酸碱添加剂,还需要微波等,稍显复杂。(Sara Preciado,Lorena Mendive-Tapia,Fernando Albericio,and Rodolfo Lavilla.Org.Chem.2013,78,8129.)(Amit Mahindra,Nitin Bagra,and Rahul Jain.J.Org.Chem.2013,78,10954.)
2006年,Reddy等报道的钯催化的sp3C-H芳基化条件,用到醋酸钯、醋酸银、碘 苯试剂。(B.V.Subba Reddy,Leleti Rajender Reddy,and,andE.J.Corey.J.Org.Lett.2006,8,3391.)
2015年,Yu课题组报道了钯催化的α-苯甘氨酸的烯基化,反应需要配体并在氧气(1atm)中进行,得到单烯基化产物。(Dastbaravardeh N,Toba T,Farmer M E,Yu,Jin-Quan.J.Am.Chem.Soc.2015,137,9877-9884.)
2016年,Chen课题组报道了钯催化的官能团导向的α-氨基酸的sp3C-H烷基化、烷氧基化,其中烷氧基化不涉及以苯甘氨酸为底物,且需加入醋酸添加剂。(Gang He,BoWang,William A.Nack,and Gong Chen.Acc.Chem.Res.2016,49,635-645.)
2014年,Chen课题组报道了钯催化的苄胺的卤化,反应体系用到过硫酸钾、卤酸钾、卤化钠等,较复杂。(Chengxi Lu,Shu-Yu Zhang,Gang He,William A.Nack,GongChen.Tetrahedron 70(2014)4197e4203.)
发明内容
本发明的目的在于提供一种条件温和、较高产率、绿色环保的合成α-苯甘氨酸衍生物及方法。
为了实现上述目的,本发明的技术方案如下:一种合成苯甘氨酸衍生物的方法,I式所示的目标产物
是通过式II所示的D-苯甘氨酸
与甲醇反应生成α-苯甘氨酸甲酯,再与式III所示的2-吡啶酰氯反应
生成式IV所示的α-苯基-α-吡啶酰胺甘氨酸甲酯
(a)芳基化:将α-苯基-α-吡啶酰胺甘氨酸甲酯IV、碘苯或取代碘苯、醋酸钯、醋酸银加入到叔戊醇溶液中,反应得双取代芳基化产物,具有较高选择性,部分伴有少量单取代芳基化产物出现,反应通式为:
优选地,以α-苯基-α-吡啶酰胺甘氨酸甲酯的摩尔量为基准(1.0equiv.),醋酸钯的摩尔用量为0.05~0.1equiv.,醋酸银的摩尔用量为1.5~2.5equiv.;碘苯或取代碘苯的摩尔用量为3.0~5.0equiv.;
(b)烷氧基化:将α-苯基-α-吡啶酰胺甘氨酸甲酯IV、醋酸钯、醋酸碘苯加入至醇和甲苯的混合溶液中,反应得双取代烷氧化产物,具有较高选择性,部分伴有少量单烷氧化产物出现,反应通式为:
优选地,以α-苯基-α-吡啶酰胺甘氨酸甲酯的摩尔量为基准(1.0equiv.),醋酸钯的摩尔量为0.05~0.1equiv.,醋酸碘苯的摩尔量为3.0~3.5equiv.,溶剂的体积比为醇:甲苯= 4:1;
(c)卤化:将α-苯基-α-吡啶酰胺甘氨酸甲酯IV、醋酸钯、NBS加入到DCE溶液中,反应得双取代卤化产物,反应式为:
优选地,以α-苯基-α-吡啶酰胺甘氨酸甲酯的摩尔量为基准(1.0equiv.),醋酸钯的摩尔量为0.05~0.1equiv.,N-溴代琥珀酰亚胺的摩尔量为3.0~4.0equiv.。
优选地,所述的α-苯基-α-吡啶酰胺甘氨酸甲酯IV通过如下步骤合成:
第一步,将D-2-苯基甘氨酸加入甲醇溶剂中,冰浴条件下缓慢加入氯化亚砜,溶液由白色悬浊液变为澄清,常温搅拌4h。反应结束后,旋蒸除去过量溶剂,用二氯甲烷旋蒸两次,带走多余氯化亚砜,得到产物D-2-苯基甘氨酸甲酯。第二步,常温搅拌下缓慢将氯化亚砜加入吡啶甲酸中,85℃下回流反应过夜。反应结束后旋蒸除去溶剂,所得红色固体为2-吡啶甲酰氯。第三步,将D-2-苯基甘氨酸甲酯溶于二氯甲烷,加入三乙胺,搅拌下缓慢分批加入至吡啶酰氯的二氯甲烷溶液中,室温下反应过夜,溶液变为棕色。反应结束后,用饱和NaHCO3洗涤有机相,用二氯甲烷反萃3次,合并有机相,用饱和食盐水洗涤,无水硫酸钠干燥,过滤,所得滤液旋蒸除去溶剂,柱层析分离得到α-苯基-α-吡啶酰胺甘氨酸甲酯。
优选地,所述的α-苯基-α-吡啶酰胺甘氨酸甲酯IV合成步骤中,第一步中的D-苯甘氨酸的摩尔量为第二步中的吡啶甲酸的摩尔量的1.19equiv.,第二步中,三乙胺的摩尔量为吡啶甲酸的摩尔量的1.1equiv.。
与现有技术相比,本发明的显著效果如下:
(1)采用广泛易得、便宜的D-苯甘氨酸为起始原料,利用过渡金属钯催化的碳氢活化的反应方法,反应条件温和,操作简便,原子经济性高,避免的常规的C-H的预活化,同时显著提高了产率,部分产率高达99%。
(2)首次采用醋酸钯作催化剂参与苯甘氨酸的C-H官能团化,对苯甘氨酸分子结构进行修饰,合成一系列新的苯甘氨酸衍生物结构,在生化、药化研究领域具有应用价值。
(3)本发明的方法适用性广,可放大到克级,只需通过延长反应时间,产率稍有下降。此外,导向官能团吡啶酰胺易除去。
附图说明
图1为实施例芳基化的核磁共振氢谱(1H NMR)、核磁共振碳谱(13C NMR),其中,图1a为实施例一中产物1a的1HNMR和13C NMR,图1b为实施例二中产物1b的1H NMR和13C NMR,图1c为实施例三中产物1c的1H NMR和13C NMR,图1d为实施例四中产物1d的1HNMR和13C NMR。
图2为实施例烷氧基化的核磁共振氢谱(1H NMR)、核磁共振碳谱(13C NMR),其中,图2a为实施例五、实施例六中产物2a的1H NMR和13C NMR,图2b为实施例七中产物2b的1HNMR和13C NMR。
图3为实施例卤化的核磁共振氢谱(1H NMR)、核磁共振碳谱(13C NMR),其中,图3a为实施例八中产物3a的1H NMR和13C NMR。
具体实施方式
上述钯催化、吡啶酰胺导向的苯甘氨酸的芳基化、烷氧基化、卤化,具体实验步骤现通过列举实施例和附图作进一步说明。
实施例一
芳基化
向15mL耐压管中加入α-苯基-α-吡啶酰胺甘氨酸甲酯(0.2mmol),碘苯(1.0mmol),Pd(OAc)2(0.02mmol),AgOAc(0.5mmol),t-AmyOH(1mL),搅拌下,130℃油浴中加热12小时,反应通过薄层色谱TLC跟踪进程。反应结束后冷却至室温,反应液过短硅胶柱(50%EA/PE-EA),滤液旋蒸除去溶剂,通过柱色谱精细分离,用乙酸乙酯/石油醚洗脱,得到产物。
产率:82%
methyl 2-([1,1':3',1″-terphenyl]-2'-yl)-2-(picolinamido)acetate(1a)
1HNMR(300MHz,CDCl3)δ8.49(d,J=4.6Hz,20H),8.39(d,J=8.4Hz,19H),8.03(d,J=7.8Hz,19H),7.85–7.67(m,27H),7.53–7.31(m,262H),7.27(d,J=7.5Hz,53H),5.86(d,J=7.0Hz,1H),3.60(s,53H).
13C NMR(75MHz,CDCl3)δ171.30,162.79,149.34,147.89,143.00,140.91,136.95,133.24,130.13,129.55,128.09,127.58,127.33,125.99,122.08,52.81,52.52.
实施例二
芳基化
向15mL耐压管中加入α-苯基-α-吡啶酰胺甘氨酸甲酯(0.2mmol),4-甲基碘苯(1.0mmol),Pd(OAc)2(0.02mmol),AgOAc(0.5mmol),t-AmyOH(1mL),搅拌下,130℃油浴中加热12小时,反应通过薄层色谱TLC跟踪进程。反应结束后冷却至室温,反应液过短硅胶柱(50%EA/PE-EA),滤液旋蒸除去溶剂,通过柱色谱精细分离,用乙酸乙酯/石油醚洗脱,得到产物。
产率:70%
methyl 2-(4,4″-dimethyl-[1,1':3',1″-terphenyl]-2'-yl)-2-(picolinamido)
acetate(1b)
1H NMR(300MHz,CDCl3)δ8.49(d,J=4.1Hz,1H),8.40(d,J=8.3Hz,1H),8.04(d,J=7.7Hz,1H),7.75(t,J=7.6Hz,1H),7.44–7.15(m,12H),6.12(d,J=8.7Hz,1H),3.61(s,3H),2.43(s,6H).
13C NMR(75MHz,CDCl3)δ171.39,162.72,149.35,147.79,142.95,138.02,137.16,137.03,133.41,130.14,129.38,128.83,127.31,126.00,122.18,52.81,52.51,21.29.
实施例三
芳基化
向15mL耐压管中加入α-苯基-α-吡啶酰胺甘氨酸甲酯(0.2mmol),4-溴碘苯(1.0mmol),Pd(OAc)2(0.02mmol),AgOAc(0.5mmol),t-AmyOH(1mL),搅拌下,130℃油浴中加热12小时,反应通过薄层色谱TLC跟踪进程。反应结束后冷却至室温,反应 液过短硅胶柱(50%EA/PE-EA),滤液旋蒸除去溶剂,通过柱色谱精细分离,用乙酸乙酯/石油醚洗脱,得到产物。
产率:87%
methyl 2-(4,4″-dibromo-[1,1':3',1″-terphenyl]-2'-yl)-2-(picolinamido)acetate(1c)
1H NMR(300MHz,CDCl3)δ8.52(d,J=4.0Hz,1H),8.31(d,J=7.9Hz,1H),8.01(d,J=7.8Hz,1H),7.77(td,J=7.7,1.7Hz,1H),7.55(d,J=8.3Hz,4H),7.46–7.30(m,2H),7.33–7.13(m,8H),5.99(d,J=8.2Hz,1H),5.99(d,J=8.2Hz,1H),3.65(s,3H).
13C NMR(75MHz,CDCl3)δ171.04,162.69,148.95,147.99,141.78,139.77,137.10,133.07,131.25,130.31,127.52,126.20,121.94,52.92,52.74.
实施例四
芳基化
向15mL耐压管中加入α-苯基-α-吡啶酰胺甘氨酸甲酯(0.2mmol),4-氯碘苯(1.0mmol),Pd(OAc)2(0.02mmol),AgOAc(0.5mmol),t-AmyOH(1mL),搅拌下,130℃油浴中加热24小时,反应通过薄层色谱TLC跟踪进程。反应结束后冷却至室温,反应液过短硅胶柱(50%EA/PE-EA),滤液旋蒸除去溶剂,通过柱色谱精细分离,用乙酸乙酯/石油醚洗脱,得到产物。
产率:80%
methyl 2-(4,4″-dichloro-[1,1':3',1″-terphenyl]-2'-yl)-2-(picolinamido)acetate(1d)
1H NMR(300MHz,CDCl3)δ8.51(d,J=4.6Hz,1H),8.33(d,J=8.1Hz,1H),8.02(d,J=7.8Hz,1H),7.76(td,J=7.7,1.5Hz,2H),7.50–7.29(m,10H),7.21(d,J=7.6Hz,2H),6.00(d,J=8.2Hz,1H),3.64(s,3H).
13C NMR(75MHz,CDCl3)δ171.06,162.67,148.94,147.94,141.81,139.27,137.17,133.72,133.19,130.85,130.37,128.31,127.52,126.23,122.05,52.91,52.74.
实施例五
烷氧基化
向15mL耐压管中加入α-苯基-α-吡啶酰胺甘氨酸甲酯(0.1mmol),Pd(OAc)2(0.005mmol),PhI(OAc)2(0.35mmol),CH3OH/toluene(体积比4/1)共1mL,搅拌下,80℃油浴中加热3小时,反应通过薄层色谱TLC跟踪进程。反应结束后冷却至室温,反应液过短硅胶柱(50%EA/PE-EA),滤液旋蒸除去溶剂,通过柱色谱精细分离,用乙酸乙酯/石油醚洗脱,得到产物。
产率:89%
methyl 2-(2,6-dimethoxyphenyl)-2-(picolinamido)acetate(2a)
1H NMR(300MHz,CDCl3)δ8.99(d,J=9.0Hz,1H),8.55(d,J=3.9Hz,1H),8.20(d,J=7.8Hz,1H),7.80(td,J=7.7,1.6Hz,1H),7.38(ddd,J=7.4,4.8,1.1Hz,1H),7.26(dd,J=9.9,6.8Hz,1H),6.62(dd,J=13.3,9.0Hz,3H),3.89(s,6H),3.69(s,3H).
13C NMR(75MHz,CDCl3)δ171.75,163.71,158.10,149.78,148.10,137.01,129.70,126.01,122.35,114.04,104.25,56.04,52.37,46.15.
实施例六
烷氧基化
向15mL耐压管中加入α-苯基-α-吡啶酰胺甘氨酸甲酯(0.1mmol),Pd(OAc)2(0.005mmol),PhI(OAc)2(0.35mmol),CH3OH 1mL,搅拌下,80℃油浴中加热3小时,反应通过薄层色谱TLC跟踪进程。反应结束后冷却至室温,反应液过短硅胶柱(50%EA/PE-EA),滤液旋蒸除去溶剂,通过柱色谱精细分离,用乙酸乙酯/石油醚洗脱,得到产物。
产率:86%
methyl 2-(2,6-dimethoxyphenyl)-2-(picolinamido)acetate(2a)
实施例七
烷氧基化
向15mL耐压管中加入α-苯基-α-吡啶酰胺甘氨酸甲酯(0.1mmol),Pd(OAc)2(0.005mmol),PhI(OAc)2(0.35mmol),CH3CH2OH/toluene(4/1)共1mL,搅拌下,120℃油浴中加热3小时,反应通过薄层色谱TLC跟踪进程。反应结束后冷却至室温,反应液过短硅胶柱(50%EA/PE-EA),滤液旋蒸除去溶剂,通过柱色谱精细分离,用乙酸乙酯/石油醚洗脱,得到产物。
产率:65%
methyl 2-(2,6-diethoxyphenyl)-2-(picolinamido)acetate(2b)
1H NMR(300MHz,CDCl3)δ9.17(d,J=9.5Hz,1H),8.55(d,J=3.9Hz,1H),8.21(d,J=7.7Hz,1H),7.80(t,J=7.7Hz,1H),7.38(dd,J=6.8,5.2Hz,1H),7.20(t,J=8.3Hz,1H),6.68(d,J=9.7Hz,1H),6.55(d,J=8.3Hz,2H),4.23–3.99(m,4H),3.69(s,3H),1.48(t,J=6.9Hz,6H).
13C NMR(75MHz,CDCl3)δ171.83,163.59,157.41,149.96,148.04,136.98,129.46,125.92,122.33,114.50,104.94,64.35,52.28,46.32,14.66.
实施例八
卤化
向15mL耐压管中加入α-苯基-α-吡啶酰胺甘氨酸甲酯(0.1mmol),Pd(OAc)2(0.005mmol),N-溴代琥珀酰亚胺(0.4mmol),搅拌下,120℃油浴中加热24小时,反应通过薄层色谱TLC跟踪进程。反应结束后冷却至室温,反应液过短硅胶柱(50%EA/PE-EA), 滤液旋蒸除去溶剂,通过柱色谱精细分离,用乙酸乙酯/石油醚洗脱,得到产物。
产率:99%
methyl 2-(2,6-dibromophenyl)-2-(picolinamido)acetate(3a)
1H NMR(300MHz,CDCl3)δ9.38(d,J=8.2Hz,1H),8.60(dd,J=4.0,0.7Hz,1H),8.33–8.03(m,1H),7.83(td,J=7.8,1.6Hz,1H),7.57(d,J=8.0Hz,2H),7.43(ddd,J=7.6,4.8,1.1Hz,1H),7.03(t,J=8.0Hz,1H),6.85(d,J=8.5Hz,1H),3.79(s,3H).
13C NMR(75MHz,CDCl3)δ169.62,163.74,149.08,148.33,137.20,136.23,132.86,130.47,126.38,122.41,56.99,53.21.。
Claims (8)
1.一种合成苯甘氨酸类衍生物的方法,其特征在于,以α-苯基-α-吡啶酰胺甘氨酸甲酯IV
为底物,通过过渡金属催化的碳氢活化得到苯甘氨酸类衍生物I
2.根据权利要求1所述的合成苯甘氨酸类衍生物的方法,所述的碳氢活化包括芳基化、烷氧基化或卤化,具体步骤如下:
(a)芳基化:将α-苯基-α-吡啶酰胺甘氨酸甲酯IV、醋酸钯、醋酸银、碘苯或取代碘苯溶于叔戊醇中,在100℃~130℃油浴加热搅拌下反应12~24h,反应结束后过短硅胶柱,旋干溶剂得粗产物,粗产物经柱层析分离后即得纯产物;
(b)烷氧基化:将α-苯基-α-吡啶酰胺甘氨酸甲酯IV、醋酸钯、醋酸碘苯溶于伯醇或仲醇与甲苯的混合液,80℃~120℃下反应3h~6h,反应结束后过短硅胶柱,旋干溶剂得粗产物,粗产物经柱层析分离后即得纯产物;
(c)卤化:将α-苯基-α-吡啶酰胺甘氨酸甲酯IV、醋酸钯、N-溴代琥珀酰亚胺溶于1,2-二氯乙烷中,100℃~130℃下反应24~36h,反应结束后过短硅胶柱,旋干溶剂得粗产物,粗产物经柱层析分离后即得纯产物。
3.根据权利要求2所述的一种合成苯甘氨酸类衍生物I的方法,其特征在于,所述的芳基化中,以底物α-苯基-α-吡啶酰胺甘氨酸甲酯的摩尔量为基准,醋酸钯的摩尔用量为0.05~0.1equiv.,醋酸银的摩尔用量为1.5~2.5equiv.;碘苯或取代碘苯的摩尔用量为 3.0~5.0equiv.。
4.根据权利要求2所述的一种合成苯甘氨酸类衍生物的方法,其特征在于,所述的烷氧基化中:以底物α-苯基-α-吡啶酰胺甘氨酸甲酯的摩尔量为基准,醋酸钯的摩尔量为0.05~0.1equiv.,醋酸碘苯的摩尔量为3.0~3.5equiv.,采用溶剂的体积比为醇:甲苯=4:1。
5.根据权利要求2所述的一种合成苯甘氨酸类衍生物的方法,其特征在于,所述的卤化中:以底物α-苯基-α-吡啶酰胺甘氨酸甲酯的摩尔量为基准,醋酸钯的摩尔量为0.05~0.1equiv.,N-溴代琥珀酰亚胺的摩尔量为3.0~4equiv.。
6.根据权利要求2所述的一种合成苯甘氨酸类衍生物的方法,其特征在于,所述的芳基化中,取代碘苯选自烷基、烷氧基、卤代烷基、卤素、氰基、酯基,取代位置为邻、间、对位。
7.根据权利要求2所述的一种合成苯甘氨酸类衍生物的方法,其特征在于,所述的烷氧基化中所用的醇为甲醇、乙醇、正丙醇、异丙醇、正丁醇或异丁醇。
8.一种基于权利要求1~7的方法合成的苯甘氨酸类衍生物,其特征在于,所述的苯甘氨酸类衍生物的结构为:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610659271.7A CN106279014A (zh) | 2016-08-11 | 2016-08-11 | 一种合成苯甘氨酸类衍生物及方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610659271.7A CN106279014A (zh) | 2016-08-11 | 2016-08-11 | 一种合成苯甘氨酸类衍生物及方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106279014A true CN106279014A (zh) | 2017-01-04 |
Family
ID=57669595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610659271.7A Pending CN106279014A (zh) | 2016-08-11 | 2016-08-11 | 一种合成苯甘氨酸类衍生物及方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106279014A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106866521A (zh) * | 2017-01-13 | 2017-06-20 | 南京理工大学 | 苯甘氨酸烷基取代类衍生物及其合成方法 |
CN106883172A (zh) * | 2017-02-17 | 2017-06-23 | 南京理工大学 | 一种苯丙氨酸类衍生物及其合成方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101654439A (zh) * | 2009-06-26 | 2010-02-24 | 上海大学 | 芳基嘧啶的邻位双卤取代化合物及其制备方法 |
US9006459B2 (en) * | 2010-07-19 | 2015-04-14 | University Of Ottawa | Fluorescent markers and use thereof for labeling specific protein targets |
-
2016
- 2016-08-11 CN CN201610659271.7A patent/CN106279014A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101654439A (zh) * | 2009-06-26 | 2010-02-24 | 上海大学 | 芳基嘧啶的邻位双卤取代化合物及其制备方法 |
US9006459B2 (en) * | 2010-07-19 | 2015-04-14 | University Of Ottawa | Fluorescent markers and use thereof for labeling specific protein targets |
Non-Patent Citations (5)
Title |
---|
ANDREI V. MALKOV等: "Asymmetric allylic substitution catalyzed by C1-symmetrical complexes of molybdenum: structural requirements of the ligand and the stereochemical course of the reaction", 《CHEMISTRY-A EUROPEAN JOURNAL》 * |
ANNA LAZAREVA等: "Direct Palladium-Catalyzed Ortho-Arylation of Benzylamines", 《ORGANIC LETTERS》 * |
HENDRICH A. CHIONG等: "Two Methods for Direct ortho-Arylation of Benzoic Acids", 《J. AM. CHEM. SOC.》 * |
LI-SHENG ZHANG等: "Direct Borylation of Primary C_H Bonds in Functionalized Molecules by Palladium Catalysis", 《ANGEW. CHEM. INT. ED.》 * |
RAED M. AL-ZOUBI等: "A Simple and Efficient Two-Step Synthesis of 1,2,3-Triiodoarenes via Consecutive C–H Iodination/ipso-Iododecarboxylation Strategy: A Potential Application towards ortho-Diiodoarenes by Regioselective Metal–Iodine Exchange Reaction", 《AUST. J. CHEM.》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106866521A (zh) * | 2017-01-13 | 2017-06-20 | 南京理工大学 | 苯甘氨酸烷基取代类衍生物及其合成方法 |
CN106883172A (zh) * | 2017-02-17 | 2017-06-23 | 南京理工大学 | 一种苯丙氨酸类衍生物及其合成方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wienand et al. | Reactions of Fischer carbene complexes with electron-deficient olefins: scope and limitations of this route to donor-acceptor-substituted cyclopropanes | |
Wu et al. | Palladium-catalyzed carbonylative synthesis of N-(2-cyanoaryl) benzamides and sequential synthesis of quinazolinones | |
Zhang et al. | C–C Activation by Retro-Aldol Reaction of Two β-Hydroxy Carbonyl Compounds: Synergy with Pd-Catalyzed Cross-Coupling To Access Mono-α-arylated Ketones and Esters | |
CN110117260A (zh) | 一种3-烷基喹喔啉-2(1h)-酮类化合物的制备方法 | |
Sibi et al. | Enantioselective radical reactions: the use of metal triflimides as Lewis acids | |
CN107954821A (zh) | 一种钌催化二苄基甲酮与内炔环化反应制备多芳取代萘衍生物的方法及应用 | |
CN106279014A (zh) | 一种合成苯甘氨酸类衍生物及方法 | |
CN106146334B (zh) | 2,3-二芳基-2-炔丙酰胺基-3-芳基氨基丙酸甲酯衍生物及其制备方法和应用 | |
Vivek Kumar et al. | Enantioselective Organozinc Addition to Aldehydes Using Planar Chiral [2.2] Paracyclophane‐Imidazoline N, O‐Ligands | |
CN110105285B (zh) | 三取代吡唑类衍生物及其制备方法 | |
Tang et al. | Efficient palladium-catalyzed Suzuki-Miyaura cross-coupling of iodoethynes with arylboronic acids under aerobic conditions | |
CN115490613B (zh) | 一种芳香腈类化合物的制备方法 | |
CN110054637A (zh) | 一种制备苯并磺内酰胺类含手性四氢吡啶骨架的不对称合成方法 | |
CN112694430B (zh) | 一种1,5-二氢-2h-吡咯-2-酮化合物的制备方法 | |
Li et al. | Synthesis of new β-hydroxy amide ligands and their Ti (IV) complex-catalyzed enantioselective alkynylation of aliphatic and vinyl aldehydes | |
CN104193667B (zh) | 一种发散型导向的氮杂环的合成方法 | |
CN108191736B (zh) | 一种2,3-二取代吲哚类衍生物及其制备方法 | |
CN108440373B (zh) | 一种铁催化的氰烷基吲哚啉及其制备方法 | |
CN112279849A (zh) | 一种n-二氟甲基氮杂吲哚类化合物及其合成方法 | |
Wang et al. | Palladium/Norbornene-Cocatalyzed Three-Component Synthesis of ortho-Acylated Benzonitriles | |
CN106957251B (zh) | 一种制备烷基硫甲基酯类化合物的方法 | |
JPH03118364A (ja) | ピリジンカルボン酸誘導体の調製方法 | |
CN106116998B (zh) | 一种立体选择性合成(z)-2,4-二取代-2-丁烯腈类化合物的方法 | |
CN105315167A (zh) | 一种2,2,3-三芳基-3-芳基氨基丙酸甲酯衍生物及其合成方法和应用 | |
CN104744283A (zh) | 茚酮羧酸酯的三氟甲基化方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170104 |
|
RJ01 | Rejection of invention patent application after publication |